Wang Na, Mei Qingyun, Wang Ziwei, Zhao Lu, Zhang Dou, Liao Dongying, Zuo Jinhui, Xie Hongxia, Jia Yingjie, Kong Fanming
Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.
Front Oncol. 2022 May 26;12:889017. doi: 10.3389/fonc.2022.889017. eCollection 2022.
Gastric cancer is an intractable malignant tumor that has the fifth highest morbidity and the third highest mortality in the world. Even though various treatment options did much to ameliorate the prognosis of advanced gastric cancer, the survival time remained unsatisfactory. It is significant to develop new therapeutic agents to improve the long-term outcome. Antibody-drug conjugate is an innovative and potent antineoplastic drug composed of a specifically targeted monoclonal antibody, a chemical linker, and a small molecule cytotoxic payload. Powerful therapeutic efficacy and moderate toxicity are its preponderant advantages, which imply the inevitable pharmaceutical developments to meet the demand for individualized precision therapy. Nevertheless, it is unavoidable that there is a phenomenon of drug resistance in this agent. This article systematically reviewed the recent progress of antibody-drug conjugates in advanced gastric cancer therapy.
胃癌是一种难治性恶性肿瘤，其发病率在全球排名第五，死亡率排名第三。尽管多种治疗方案在很大程度上改善了晚期胃癌的预后，但生存时间仍不尽人意。开发新的治疗药物以改善长期疗效具有重要意义。抗体药物偶联物是一种创新且有效的抗肿瘤药物，由特异性靶向单克隆抗体、化学连接子和小分子细胞毒性药物组成。强大的治疗效果和适度的毒性是其突出优势，这意味着必然会有药物研发以满足个体化精准治疗的需求。然而，这种药物不可避免地存在耐药现象。本文系统综述了抗体药物偶联物在晚期胃癌治疗中的最新进展。
